AMLX - Amylyx Pharmaceuticals Inc
IEX Last Trade
2.21
0.090 4.072%
Share volume: 414,060
Last Updated: Fri 30 Aug 2024 09:59:39 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$2.12
0.09
4.25%
Fundamental analysis
25%
Profitability
17%
Dept financing
5%
Liquidity
75%
Performance
25%
Performance
5 Days
-0.45%
1 Month
16.23%
3 Months
32.14%
6 Months
-88.66%
1 Year
-89.80%
2 Year
-90.76%
Key data
Stock price
$2.21
DAY RANGE
N/A - N/A
52 WEEK RANGE
$1.58 - $22.02
52 WEEK CHANGE
-$0.90
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO:
Region: US
Website: amylyx.com
Employees: 259
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: amylyx.com
Employees: 259
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis.
Recent news